Abbisko Cayman Limited (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 11.88
+0.54 (4.76%)
At close: Mar 6, 2026
Abbisko Cayman Market Cap
Abbisko Cayman has a market cap or net worth of 7.99 billion as of March 6, 2026. Its market cap has increased by 159.12% in one year.
Market Cap
7.99B
Enterprise Value
5.66B
Revenue
681.17M
Ranking
n/a
PE Ratio
118.62
Stock Price
11.88
Market Cap Chart
Since October 15, 2021, Abbisko Cayman's market cap has decreased from 8.71B to 7.99B, a decrease of -8.30%. That is a compound annual growth rate of -1.95%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 7.99B | -8.69% |
| Dec 31, 2025 | 8.75B | 204.13% |
| Dec 31, 2024 | 2.88B | 21.63% |
| Dec 29, 2023 | 2.36B | 4.97% |
| Dec 30, 2022 | 2.25B | -64.77% |
| Dec 31, 2021 | 6.39B | -26.60% |
| Oct 15, 2021 | 8.71B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Guangzhou Innogen Pharmaceutical Group | 11.11B |
| Nanjing Leads Biolabs | 10.86B |
| Shanghai Haohai Biological Technology | 9.98B |
| HBM Holdings | 9.53B |
| CStone Pharmaceuticals | 9.22B |
| CK Life Sciences Int'l., (Holdings) | 7.69B |
| Alphamab Oncology | 7.68B |
| Lepu Biopharma | 7.36B |